



The Digital Examiner
www.prostaid.org

“Issue #306” June 2025



Guest Speaker June 18th



Feven Gebregiorgis

I'm well experienced LPN with a demonstrated history of working in the health wellness and fitness industry. Skilled in Home Care, Nursing, Customer Service, Healthcare, and Microsoft Office. Strong healthcare services professional with a Nursing focused in Practical Nursing, Vocational Nursing and Nursing Assistants from Mohawk College.

Miracle Home Care is a reliable care provider with a focus on improving the lives of each individual and family we serve. Our goal is to provide a better care option for loved ones who want to remain in their home or stay close to their family as they age in place, deal with their disability, or recover from their health condition. We want our clients to achieve their full potential in living their day-to-day life by receiving the right care that's tailored to their unique needs and preferences.

Miracle Home Care

Upcoming Events



Mark This Date & Come And Join Us For Our 3rd Annual Picnic On July 16th
More Details Coming

All of our monthly General meetings are in person or via Zoom

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB

If you are interested in attending via Zoom please sign up HERE

Warriors & Wives Partners and Caregivers

Join us on Wednesday, June 18th. We are meeting at CKE starting at 6:00 pm with a social gathering in the lounge and separate meetings from 6:30 to 7:30 prior to the general meeting in the main hall.



Warriors Lunch

Reminder to all our Warriors that our next pizza lunch at Bella Roma Pizza in Lakeview is scheduled for **Tuesday August 5th** starting at 11:30 am.

Contact Jim to confirm your attendance and don't forget to bring \$20 to help cover the cost.
[RSVP jim.richardson@telus.net](mailto:jim.richardson@telus.net)

Bella Roma Pizza #17 6449 Crowchild Tr. SW.

Exciting Opportunity Alert! ProstaId Calgary is on the lookout for passionate individuals eager to make a real difference. Join us as a Board Member and play a vital role in our impactful mission. Your skills and dedication can help shape a brighter future. "If you believe this is the perfect opportunity for you, we'd love to hear from you!

Reach out to any of our Board members or connect with me directly at program.director@prostaId.org.



Donate Today

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

Donate Today

Connect With Us

**Information
Phone 403 455 1916
info@prostaId.org
Brad Sterling
President
president@prostaId.org**

Connect With Us

Support Groups

**Jim Richardson
Warriors
jim.richardson@telus.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaId.org**

Meeting Info Here

Articles Of Interest



DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 50 to 70 years of age

-No appointment necessary

-Testing ages 40 to 80

-Find the next community clinic near you

-15 minutes can save your life!

MAN VAN UPCOMING CLINICS



T cells can sense testosterone— What does that mean for prostate cancer therapies?


Spatial transcriptomics gives scientists a way to track where immune cells are located (the "spatial" part) and exactly how those immune cells are trying to protect the body (the "transcriptomics" part).

By tracking this immune-cell activity, Dr. Reina-Campos can help guide the development of new immunotherapies for prostate cancer, a disease that kills around 35,700 men each year.

[More Trial Info](#)

April 2025
MedicalXpress

Testosterone




Pivotal trial launches of ⁶⁴Cu-SAR-bisPSMA in BCR of prostate cancer

The first clinical trial site has been activated in the pivotal phase 3 AMPLIFY trial (NCT06970847), evaluating the efficacy and safety of ⁶⁴Cu-SAR-bisPSMA in patients with biochemical recurrence (BCR) of prostate cancer, Clarity Pharmaceuticals announced in a news release.

[More Info](#)

May 2025
Urology Times

Pivotal Trial



Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer

Radical prostatectomy was found to have lesser toxicity compared with the combination modalities for patients undergoing localized therapy for prostate cancer

Of the 47,387 patients enrolled, 39.7% experienced a genitourinary complication during the specific period. The most common included urinary incontinence (11.7%), kidney failure (8.8%), bladder disorder (2.9%), and cystitis (2.3%).

April 2025
Cancernetwork

Radical



Hyperbaric oxygen treatment helps cancer patients reclaim normal life after radiation side effects

Hyperbaric oxygen treatment provides long-term relief for patients suffering from late radiation-induced injuries after treatment of cancer in the lower abdominal area. Five years after hyperbaric oxygen therapy, the positive effects remain. This has been shown in a study conducted at the University of Gothenburg.

April 2025
Oncology & Cancer

Hyperbaric



Shorter radiation therapy after prostate surgery safe, study finds

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many patients decline or defer radiation because it requires daily sessions for several weeks.

[More Info Here](#)

May 2025
MedicalXpress

Radiation




PSMA-PET Staging Tied to Lower BCR Risk After RP for Very High-Risk Prostate Cancer

The finding from a retrospective study may have implications for staging and selecting optimal surgical candidates among men with very high-risk prostate cancer, according to Alessandro Viti, MD, of the Università Vita-Salute San Raffaele in Milan, Italy, and colleagues.

[Trial Updates](#)

May 2025
Renal+Urology

PSMA-PET




Bounce effect or local recurrence after low-dose-rate brachytherapy of the prostate? When prostate-specific membrane antigen positron emission tomography-computed tomography is false positive:

Low-dose-rate brachytherapy has been increasingly utilized as a minimally invasive treatment option in patients with low- and intermediate-risk prostate cancer. Following 1-2 years of treatment, a "bounce phenomenon" might occur in approximately 30% of patients undergoing low-dose-rate brachytherapy, characterized by a transient rise in prostate-specific antigen levels followed by a subsequent decrease.

[Trial Results](#)

May 2025
URO Today

Brachytherapy




SBRT may offer a safe alternative to CFRT after prostatectomy

“This approach could remove a major barrier to post-surgery radiation therapy,” explained senior author Amar U. Kishan, MD, executive vice chair of radiation oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), in a news release on the findings.² “SBRT shortens treatment time, reduces health care costs, and may have biological advantages in targeting prostate cancer.

Trial Results

April 2025
Renal+Urology

SBRT



ClarityDX technology can be used to predict the risk of disease.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.

ClarityDX

Read about these articles below

- 1-Joe Biden has prostate cancer
- 2-Radiation Reduces Incidence of ED
- 3-Vitamin D
- 4-Avoiding unnecessary surgery
- 5-Exercise improves erectile function
- 6-Surgical Over-treatment
- 7-Advanced imaging and targeted therapy
- 8- Genomic vs Genetic Testing in Prostate Cancer
- 9-Canadian Prostate Cancer Guide
- 10-A Conversation with Lorelei Mucci

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



Articles For Everyone




Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know

The diagnosis was made after he sought medical help for worsening urinary symptoms—a decision that likely saved his life. A small nodule on his prostate led to further investigation, revealing a high-grade cancer with a Gleason score of nine out of ten. This score indicates one of the most aggressive and fast-growing types of prostate cancer.

May 2025
The Conversation

Joe Biden



Neurovascular Sparing during Radiation Reduces Incidence of ED in Prostate Cancer

“However, with the enhanced precision of MR-guidance, we gain the confidence to limit – or deescalate – the dose they receive. In short, the prostate gets the therapeutic dose while the erectile tissues receive a much lower dose, thus preserving their function.”

May 2025
Cancernetwork

ED



Vitamin D Mitigated Side Effects of Cancer Treatment and Supported Bone Health

Despite the heterogeneity of methodologies across studies, evidence suggested that vitamin D plays a critical role in reducing treatment-associated adverse events, such as peripheral neuropathy, nausea, and fatigue. In addition, maintaining adequate levels of vitamin D may help preserve bone density, particularly in patients undergoing preoperative chemoradiotherapy.

Study Details

May 2025
Renal + Urology News

Vitamin D




More men with prostate cancer are avoiding unnecessary surgery

Prostate cancer is a leading cause of cancer-related death among men in the United States. Despite this, widespread adoption of prostate cancer screening has been controversial. Many primary care doctors worry that screening will lead to unnecessary surgery for men with low-risk prostate cancer and current guidelines recommend screening only after discussing the risk of overtreatment with the patient.

More Info Here

May 2025
MedicalXpress

Surgery




New study finds that exercise improves erectile function after treatment

The study was of 112 men who had previously undergone or were currently undergoing treatment for prostate cancer and were concerned about sexual dysfunction, with one group going through normal care and the other having an additional six-months of supervised, group-based resistance and aerobic exercise. After the period, the men on the exercise programme had significantly higher erectile function scores.

April 2025
Europa Uomo

Exercise



Surgical Over-treatment Has Declined in Grade Group 1 Prostate Cancer

Among patients who received prostatectomy for grade group 1 disease in the SEER cohort, the likelihood of experiencing any higher risk feature increased from 26% in 2010 to 41% in 2020. In 2010 and 2020, respectively, the rates of biopsy grade group 2 or higher were 17% vs 28%, the rates of more than 50% biopsy cores were 10% vs 15%, and the rates of preoperative PSA levels of at least 10 were 9.2% vs 13%.

April 2025
Cancernetwork

Over-treatment




Advanced imaging and targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

Prostate cancer is the most common non-skin cancer among American men, with about one in eight diagnosed during their lifetime. Many of these cancers are low risk and grow so slowly they may never cause symptoms. But despite growing acceptance of active surveillance many men still opt for surgery or radiation out of fear the cancer could become dangerous, which can cause significant long-term side effects such as incontinence or sexual dysfunction.

May 2025
UCLA Health

Imaging




The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer

To begin, the distinction between a genomic biomarker vs germline testing was mentioned. A genomic biomarker includes a measurable DNA or RNA characteristic that can be used to indicate normal biological processes, disease, or response to treatment. Germline testing is the analysis of DNA to identify genetic variations that may be associated with health risks or cancer predisposition.

[More Info Here](#)

May 2025
Cancernetwork

Genomic vs Gentic



Bringing you the most up to date information in treatments, support, well-being, and more all in one place

We can help you in achieving the support you’re looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

Learn More Here



What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader

“I had a chance to meet somebody who completely changed my life. His name was Dimitrios Trichopoulos and he was a really world-famous cancer epidemiologist. It was his excitement and passion for cancer that truly sparked my own interest in the field. In many ways, I believe my career and life have been shaped by serendipity—by being open to chance and willing to take different paths.”

April 2025
Cancerworld

Lorelei Mucci

Thank you to our Sponsors and Community Partners

Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on PROSTAID Calgary Society’s website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)